Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
Autore:
Bos, AME; de Graaf, H; de Vries, EGE; Piersma, H; Willemse, PHB;
Indirizzi:
Univ Groningen Hosp, Div Med Oncol, Dept Internal Med, NL-9700 RB Groningen, Netherlands Univ Groningen Hosp Groningen Netherlands NL-9700 RB ningen, Netherlands Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands Med Ctr Leeuwarden Leeuwarden Netherlands Med, Leeuwarden, Netherlands Martini Hosp, Dept Internal Med, Groningen, Netherlands Martini Hosp Groningen Netherlands Internal Med, Groningen, Netherlands
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 12, volume: 82, anno: 2000,
pagine: 1920 - 1924
SICI:
0007-0920(200006)82:12<1920:FOADCR>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
STAGE-II; CHEMOTHERAPY; CARCINOMA; SCHEDULE; TRIAL; CYCLOPHOSPHAMIDE; RADIOTHERAPY; METHOTREXATE; DOXORUBICIN; IRRADIATION;
Keywords:
adjuvant chemotherapy; breast cancer; CMF; dose intensity; granulocyte colony stimulating factor; premenopausal;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Bos, AME Univ Groningen Hosp, Div Med Oncol, Dept Internal Med, POB 30 001, NL-9700RB Groningen, Netherlands Univ Groningen Hosp POB 30 001 Groningen Netherlands NL-9700 RB
Citazione:
A.M.E. Bos et al., "Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer", BR J CANC, 82(12), 2000, pp. 1920-1924

Abstract

Our aim was to study the feasibility of an intensified intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) schedule with the aim to escalate dose intensity (DI). Twenty-three premenopausal breast cancer patients received 6 cycles of adjuvant CMF intravenously on days 1. and 8 every 3 weeks and granulocyte colony-stimulating factor days 9-18. Endpoints wereDI and toxicity. Twenty-one out of 23 patients (91%) received the projected total dose and reached greater than or equal to 85% of the projected Dl, Compared to 'classical' CMF, all patients reached greater than or equal to 111% DI. Nine patients received the planned schedule without delay. Thirteen patients (57%) were treated for infection and four patients (17%) were hospitalized for febrile neutropenia. Twelve patients received red blood celltransfusions (52%). Radiation therapy (n = 6) had no adverse impact on dose intensity or haematological toxicity. This dose-intensified CMF schedule was accompanied by enhanced haematological toxicity with clinical sequelae,namely fever, intravenous antibiotics and red blood cell transfusions, butallows a high dose intensity in a majority of patients. (C) 2000 Cancer Research Campaign.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 09:26:44